A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Status:
Recruiting
Trial end date:
2024-11-25
Target enrollment:
Participant gender:
Summary
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of
upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to
placebo in combination with a 52-week CS taper regimen, as measured by the proportion of
participants in sustained remission at Week 52, and to assess the safety and tolerability of
upadacitinib in participants with giant cell arteritis (GCA). The objective of period 2 is to
evaluate the safety and efficacy of continuing versus withdrawing upadacitinib in maintaining
remission in participants who achieved remission in Period 1.